Skip to main content

Table 3 Cost-effectiveness analysis results of the included studies

From: Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review

Study

Economic Study Design

Year to Which Costs Applied

Currency Used to Which Cost Applied

Cost of Study Intervention

Cost of Study Control

Incremental Cost

Total LYs of Intervention

Total LYs of Control

Total QALYs of Intervention

Total QALYs of Control

Incremental cost per LYG

Incremental cost per QALY

|ICER|

Chaudhary (2021)

Model-Based

2019

CAD and SEK

CAD 147,890 and SEK 736,478

CAD 51,439 and SEK 201,146

CAD 96,451 and SEK 535,333

CAD 1.77 and SEK 2.33

CAD 0.91 and SEK 1.29

CAD 1.29 and SEK 1.70

CAD 0.60 and SEK 0.95

CAD 112,921 and SEK 417,693

CAD 140,753 and SEK 568,895

NA

Gao (2018)

Model-Based

2017

USD

PS model: USD 137,935 and Markov model USD 100,236

PS model: USD 119,257 and Markov model USD 22,534

PS model: USD 118,678 and Markov model USD 77,702

PS model: 1.51 and Markov model 1.32

PS model: 0.86 and Markov model 0.91

PS model: 1.06 and Markov model 1.03

PS model: 0.86 and Markov model 0.68

NA

NA

PS model: 17,239 and Markov model 26,570

Goeree (2016)

Model-Based

2015

USD

PS model: USD 139,017 and Markov model USD 139,016

PS model: USD 38,849 and Markov model USD 38,812

PS model: USD 100,168 and Markov model USD 100,204

PS model: 1.69 and Markov model 1.68

PS model: 0.87 and Markov model 0.87

PS model: 1.24 and Markov model 1.23

PS model: 0.58 and Markov model 0.58

PS model: USD 121,905 and Markov model USD 122,834

PS model: USD 151,560 and Markov model USD 152,229

NA

Hu (2023)

Model-Based

2019

USD

USD 478,830

USD 264,477

USD 214,353

NA

NA

NA

NA

USD159,834

USD 190,919

207,388

Insinga (2019)

Model-Based

2018

USD

USD 231,209

USD 111,758

USD 119,451

3.4

1.76

2.8

1.41

USD72,725

USD 86,293

NA

Chen (2022)

Model-Based

2021

USD

USD 12,321

USD 36,371

USD24,050

1.84

1.74

0.99

1

NA

USD 1,314,280

NA

Cheng (2022)

Model-Based

2021

USD

USD 12,203

USD 14,045

USD 1842

NA

NA

1.37

1.52

NA

USD 12,694

NA

Chouaid (2019)

Model-Based

2017

EUR

EUR 125,261

EUR 63,229

EUR 62,032

2.14

1.21

1.57

0.83

NA

EUR 84,097

66,825

Liu (2022)

Model-Based

2021

USD

USD 153,892

USD 150,444

USD 3,449

NA

NA

NA

NA

NA

USD 15,613

NA

Rothwell (2021)

Model-Based

2015

GBP

GBP 46,711

GBP 15,430

GBP 31,281

NA

NA

1.39

0.51

NA

GBP 35,657

33,134

Shao (2022)

Model-Based

2021

USD

USD 19,165.08

USD 12,817.27

USD 6347.81

2.38

1.47

NA

NA

NA

NA

13571.68

Zhang (2023)

Model-Based

2021

USD

USD 45,268

USD 26,768

USD 18,501

NA

NA

1.4

0.83

NA

NA

32,237

Zhao (2023)

Model-Based

2022

USD

USD 19,026

USD 18,131

USD 895

2.513

2.219

1.603

1.283

NA

NA

NA

Zhou (2023)

Model-Based

2022

USD

USD 23,674

USD 11,367

USD 12,307

NA

NA

1.61

0.94

NA

NA

18,369

Li (2022)

Model-Based

2021

USD

USD 80,540.73

USD 24,726.85

USD 55,813.88

NA

NA

1.58

1

NA

NA

96,230.83

  1. ICER: incremental cost-effectiveness ratios;QALY: quality-adjusted life year; LY, life-year; LYG, life-year gained; NSCLC, non-small cell lung cancer; USD, United States Dollar; CAD, Canadian Dollar; SEK, Swedish Krona; EUR, Euro; GBP, British Pound Sterling